Neurocrine Biosciences, Inc. (NBIX) Posts Q3 EPS of $0.56, Revenues Rose 189% Y/Y
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $161.62 +2.10%
EPS Growth %: -5.5%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -5.5%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
